IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
Rhea-AI Summary
IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced its participation in two major investor relations events in February 2025. The company will be featured at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11th at 1:20 PM ET, where President and CEO Yujiro S. Hata will participate in a fireside chat hosted by Matthew Biegler.
Additionally, IDEAYA will join Citi's 2025 Virtual Oncology Leadership Summit on February 19th at 12:00 PM ET, featuring another fireside chat with CEO Hata, hosted by Yigal D. Nochomovitz. Live audio webcasts of these events will be available on the company's investor relations website, with recordings accessible for 30 days after the events.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, IDYA gained 0.76%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Oppenheimer 35th Annual Healthcare Life Sciences Conference
Tuesday, February 11th, 2025 at 1:20 PM ET
- Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Matthew Biegler, Executive Director and Senior Analyst
Citi's 2025 Virtual Oncology Leadership Summit
Wednesday, February 19th, 2025 at 12:00 PM ET
- Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst
A live audio webcast of the conference event, as permitted by the conference host, will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcast will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-february-2025-investor-relations-events-302360092.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
When is IDEAYA Biosciences (IDYA) presenting at the Oppenheimer Healthcare Conference in 2025?
What investor conferences is IDYA attending in February 2025?
How long will IDYA's February 2025 conference webcasts be available for replay?
Where can investors access IDYA's February 2025 conference presentations?
